ARA-290 peptide — Labelled as containing ARA-290, a synthetic peptide also known as cibinetide.

30 mg labelled content — Presented as a 30 mg product. This identifies the labelled content, not an amount per dose or pen increment.

Multidose pen format — Supplied in a pen-format presentation rather than a single-dose format.

Innate repair receptor research — ARA-290 has been investigated for its interaction with signalling pathways associated with inflammatory responses and cellular protection.

Small-nerve-fibre research focus — Published studies have explored the compound in sarcoidosis-associated small-fibre neuropathy and neuropathic symptoms in people with type 2 diabetes.

Neuropathic Pain: 2–4 mg daily (20–40 clicks)

Inflammation: 1–2 mg daily (10–20 clicks)

Nerve Regeneration: 4–6 mg daily (40–60 clicks)

What is Noventra Pharma ARA-290 30 mg?

This is a multidose pen-format product labelled as containing 30 mg of ARA-290, a synthetic peptide also known as cibinetide.

What is ARA-290 being studied for?

ARA-290 has been investigated in research involving small-fibre neuropathy, inflammatory signaling and cellular responses to tissue injury. These research areas should not be interpreted as proven benefits of this finished product.

How does ARA-290 relate to cellular-protection research?

Researchers have studied ARA-290's interaction with the innate repair receptor, a signaling pathway associated with inflammatory responses and tissue-protection mechanisms. Its potential effects remain under investigation.

Has ARA-290 been studied in humans?

The research described in this listing includes small clinical studies in people with sarcoidosis-associated small-fibre neuropathy and in people with type 2 diabetes who experienced neuropathic symptoms. Some selected outcomes were encouraging, but findings were exploratory or mixed and require further confirmation.

Does 30 mg mean the amount per dose?

The listing identifies the product as a 30 mg multidose pen; it does not specify an amount per dose or per pen increment. Do not interpret 30 mg as a single-dose instruction.

ARA-290 (cibinetide): research overview

ARA-290 is a synthetic peptide designed from the structure of erythropoietin to investigate signalling through the innate repair receptor. Published research has explored inflammatory responses, tissue protection and small-nerve-fibre changes. The studies below concern the investigational compound, not the Noventra Pharma 30 mg multidose pen. They do not establish the efficacy, safety, purity or equivalence of this finished product.

1. Sarcoidosis-associated neuropathy: randomized pilot study

This double-blind, placebo-controlled exploratory trial enrolled 22 people with sarcoidosis and symptoms of small-fibre neuropathy. Over four weeks, the ARA-290 group showed a greater improvement in the Small Fiber Neuropathy Screening List score than the placebo group. However, Brief Pain Inventory and fatigue scores improved similarly in both groups. This distinction matters: an improvement on one symptom measure does not demonstrate a consistent benefit across pain and fatigue outcomes. The small sample and short study period limit conclusions about effectiveness and longer-term safety.

Read the study: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy

2. Corneal nerve-fibre density and neuropathic symptoms

A blinded, placebo-controlled trial investigated ARA-290 over 28 days in people with documented sarcoidosis-associated small-nerve-fibre loss and damage. Researchers reported improvements in neuropathic symptoms together with increased corneal small-nerve-fibre density, changes in temperature sensitivity and improved performance on a six-minute walk test. These findings are relevant to nerve-fibre research, but corneal measurements are not proof of nerve repair throughout the body. Findings from this specific patient group cannot automatically be extended to other causes of neuropathy or to a commercially supplied pen.

Read the study: ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

3. Type 2 diabetes and neuropathic symptoms

A phase 2 placebo-controlled study evaluated ARA-290 in people with type 2 diabetes and painful neuropathy, with 28 days of treatment followed by a further month of observation. The abstract reports improvements in HbA1c, lipid profiles and neuropathic symptoms assessed using PainDetect. Increased corneal nerve-fibre density was reported in a subgroup with more marked baseline nerve-fibre loss. A subgroup finding should not be interpreted as a benefit for every participant or for everyone with diabetes. These short-term results support further investigation rather than establish a diabetes or neuropathy treatment.

Read the study: ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes